STOCK TITAN

[6-K] High-Trend International Group Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Regencell Bioscience Holdings Limited (RGC) filed a Form 6-K with the U.S. SEC for the month of June 2025. The submission is largely administrative in nature and furnishes, pursuant to Nasdaq Rule 5250(c)(2), the company’s unaudited condensed consolidated interim balance sheets and statements of operations and comprehensive loss for the six-month period ended 31 December 2024. These financial statements are provided as Exhibit 99.1, titled “Regencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results.” No detailed line-item financial data, earnings guidance, or strategic initiatives are included in the body of the filing. The document also contains standard signature and filing-cover information confirming that Regencell continues to file its annual reports on Form 20-F.

Because the actual financial tables are presented only in the attached exhibit and not within the filing text supplied, investors will need to review Exhibit 99.1 separately to evaluate revenue trends, profitability, liquidity, or other key performance indicators. Overall, the filing appears routine and does not announce any major transactions, capital raises, or changes in corporate governance.

Regencell Bioscience Holdings Limited (RGC) ha presentato un Modulo 6-K alla SEC statunitense relativo al mese di giugno 2025. La presentazione è principalmente di natura amministrativa e, ai sensi della Regola Nasdaq 5250(c)(2), fornisce i bilanci consolidati intermedi abbreviati non revisionati e i rendiconti delle operazioni e delle perdite complessive per il periodo di sei mesi terminato il 31 dicembre 2024. Questi rendiconti finanziari sono allegati come Esibizione 99.1, intitolata “Regencell Bioscience Holdings Limited Annuncia i Risultati Finanziari della Prima Metà del 2025.” Nel testo della presentazione non sono inclusi dati finanziari dettagliati per voce, previsioni sugli utili o iniziative strategiche. Il documento contiene inoltre le informazioni standard relative alle firme e alla copertura della presentazione, confermando che Regencell continua a presentare i suoi rapporti annuali con il Modulo 20-F.

Poiché le tabelle finanziarie vere e proprie sono presentate solo nell’allegato e non nel testo della presentazione, gli investitori dovranno esaminare separatamente l’Esibizione 99.1 per valutare l’andamento dei ricavi, la redditività, la liquidità o altri indicatori chiave di performance. Nel complesso, la presentazione appare di routine e non annuncia transazioni importanti, raccolte di capitale o cambiamenti nella governance aziendale.

Regencell Bioscience Holdings Limited (RGC) presentó un Formulario 6-K ante la SEC de EE. UU. correspondiente al mes de junio de 2025. La presentación es principalmente administrativa y, conforme a la Regla Nasdaq 5250(c)(2), proporciona los estados financieros consolidados interinos condensados no auditados y los estados de operaciones y pérdidas integrales para el período de seis meses finalizado el 31 de diciembre de 2024. Estos estados financieros se incluyen como Anexo 99.1, titulado “Regencell Bioscience Holdings Limited Anuncia Resultados Financieros de la Primera Mitad de 2025.” No se incluyen datos financieros detallados por partida, pronósticos de ganancias ni iniciativas estratégicas en el cuerpo del informe. El documento también contiene la información estándar de firmas y portada que confirma que Regencell continúa presentando sus informes anuales en el Formulario 20-F.

Dado que las tablas financieras reales se presentan únicamente en el anexo adjunto y no en el texto del informe, los inversores deberán revisar por separado el Anexo 99.1 para evaluar las tendencias de ingresos, rentabilidad, liquidez u otros indicadores clave de desempeño. En general, la presentación parece rutinaria y no anuncia transacciones importantes, aumentos de capital ni cambios en la gobernanza corporativa.

Regencell Bioscience Holdings Limited (RGC)는 2025년 6월분에 대해 미국 증권거래위원회(SEC)에 Form 6-K를 제출했습니다. 이번 제출은 주로 행정적인 성격이며, Nasdaq 규칙 5250(c)(2)에 따라 감사되지 않은 간략 통합 중간 재무상태표 및 2024년 12월 31일 종료된 6개월 기간의 영업실적 및 포괄손실 보고서제공합니다. 해당 재무제표는 “Regencell Bioscience Holdings Limited, 2025년 상반기 경영 재무 결과 발표”라는 제목의 첨부서류 99.1로 제공됩니다. 제출 문서 본문에는 상세한 항목별 재무 데이터, 수익 전망 또는 전략적 계획이 포함되어 있지 않습니다. 또한, Regencell이 계속해서 연례 보고서를 Form 20-F로 제출하고 있음을 확인하는 표준 서명 및 제출 표지 정보도 포함되어 있습니다.

실제 재무 표는 첨부된 서류에만 포함되어 있고 제출 문서 본문에는 없기 때문에, 투자자들은 수익 동향, 수익성, 유동성 또는 기타 주요 성과 지표를 평가하기 위해 별도로 첨부서류 99.1을 검토해야 합니다. 전반적으로 이번 제출은 일상적인 것으로 보이며, 주요 거래, 자본 조달 또는 기업 지배구조 변경 사항을 발표하지 않습니다.

Regencell Bioscience Holdings Limited (RGC) a déposé un formulaire 6-K auprès de la SEC américaine pour le mois de juin 2025. Cette soumission est principalement de nature administrative et fournit, conformément à la règle Nasdaq 5250(c)(2), les bilans consolidés intermédiaires condensés non audités ainsi que les comptes de résultat et pertes globales pour la période de six mois close le 31 décembre 2024. Ces états financiers sont fournis en tant que Pièce 99.1, intitulée « Regencell Bioscience Holdings Limited annonce les résultats financiers de la première moitié de 2025 ». Aucun détail financier par poste, prévisions de bénéfices ou initiatives stratégiques ne figure dans le corps du document. Le document contient également les informations standard relatives aux signatures et à la couverture de dépôt confirmant que Regencell continue de déposer ses rapports annuels sur le formulaire 20-F.

Étant donné que les tableaux financiers réels sont présentés uniquement dans la pièce jointe et non dans le texte du dépôt, les investisseurs devront consulter séparément la Pièce 99.1 pour évaluer les tendances des revenus, la rentabilité, la liquidité ou d’autres indicateurs clés de performance. Dans l’ensemble, le dépôt semble routinier et n’annonce aucune transaction majeure, levée de fonds ou changement dans la gouvernance d’entreprise.

Regencell Bioscience Holdings Limited (RGC) reichte ein Formular 6-K bei der US-SEC für den Monat Juni 2025 ein. Die Einreichung ist hauptsächlich administrativer Natur und liefert gemäß Nasdaq-Regel 5250(c)(2) die ungeprüften, verkürzten konsolidierten Zwischenbilanzen sowie Gewinn- und Verlustrechnungen und Gesamtergebnisrechnungen für den sechsmonatigen Zeitraum zum 31. Dezember 2024. Diese Finanzberichte sind als Anlage 99.1 beigefügt und tragen den Titel „Regencell Bioscience Holdings Limited gibt Management-Finanzergebnisse für das erste Halbjahr 2025 bekannt.“ Im Haupttext der Einreichung sind keine detaillierten Finanzdaten nach Position, Gewinnprognosen oder strategischen Initiativen enthalten. Das Dokument enthält zudem die üblichen Unterschrifts- und Einreichungsinformationen, die bestätigen, dass Regencell weiterhin seine Jahresberichte in Form 20-F einreicht.

Da die eigentlichen Finanztabellen nur im Anhang und nicht im Text der Einreichung enthalten sind, müssen Anleger Anlage 99.1 separat prüfen, um Umsatztrends, Rentabilität, Liquidität oder andere wichtige Leistungskennzahlen zu bewerten. Insgesamt wirkt die Einreichung routinemäßig und kündigt keine wesentlichen Transaktionen, Kapitalerhöhungen oder Änderungen in der Unternehmensführung an.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 6-K furnishing interim statements; no new strategic or financial surprises—impact neutral.

This 6-K merely transmits unaudited financial statements for the six months ended 31 Dec 2024, fulfilling Nasdaq’s periodic-reporting rule. Without the underlying numbers, investors cannot assess revenue momentum, cash burn, or margin trends from the submission alone. Importantly, the filing does not disclose new financing, M&A, regulatory approvals, or material events that would typically move the share price. As such, it should be viewed as a procedural update rather than a value-changing catalyst. Investors should consult Exhibit 99.1 to perform any meaningful financial analysis, but based on the information provided here, the market impact is expected to be negligible.

Regencell Bioscience Holdings Limited (RGC) ha presentato un Modulo 6-K alla SEC statunitense relativo al mese di giugno 2025. La presentazione è principalmente di natura amministrativa e, ai sensi della Regola Nasdaq 5250(c)(2), fornisce i bilanci consolidati intermedi abbreviati non revisionati e i rendiconti delle operazioni e delle perdite complessive per il periodo di sei mesi terminato il 31 dicembre 2024. Questi rendiconti finanziari sono allegati come Esibizione 99.1, intitolata “Regencell Bioscience Holdings Limited Annuncia i Risultati Finanziari della Prima Metà del 2025.” Nel testo della presentazione non sono inclusi dati finanziari dettagliati per voce, previsioni sugli utili o iniziative strategiche. Il documento contiene inoltre le informazioni standard relative alle firme e alla copertura della presentazione, confermando che Regencell continua a presentare i suoi rapporti annuali con il Modulo 20-F.

Poiché le tabelle finanziarie vere e proprie sono presentate solo nell’allegato e non nel testo della presentazione, gli investitori dovranno esaminare separatamente l’Esibizione 99.1 per valutare l’andamento dei ricavi, la redditività, la liquidità o altri indicatori chiave di performance. Nel complesso, la presentazione appare di routine e non annuncia transazioni importanti, raccolte di capitale o cambiamenti nella governance aziendale.

Regencell Bioscience Holdings Limited (RGC) presentó un Formulario 6-K ante la SEC de EE. UU. correspondiente al mes de junio de 2025. La presentación es principalmente administrativa y, conforme a la Regla Nasdaq 5250(c)(2), proporciona los estados financieros consolidados interinos condensados no auditados y los estados de operaciones y pérdidas integrales para el período de seis meses finalizado el 31 de diciembre de 2024. Estos estados financieros se incluyen como Anexo 99.1, titulado “Regencell Bioscience Holdings Limited Anuncia Resultados Financieros de la Primera Mitad de 2025.” No se incluyen datos financieros detallados por partida, pronósticos de ganancias ni iniciativas estratégicas en el cuerpo del informe. El documento también contiene la información estándar de firmas y portada que confirma que Regencell continúa presentando sus informes anuales en el Formulario 20-F.

Dado que las tablas financieras reales se presentan únicamente en el anexo adjunto y no en el texto del informe, los inversores deberán revisar por separado el Anexo 99.1 para evaluar las tendencias de ingresos, rentabilidad, liquidez u otros indicadores clave de desempeño. En general, la presentación parece rutinaria y no anuncia transacciones importantes, aumentos de capital ni cambios en la gobernanza corporativa.

Regencell Bioscience Holdings Limited (RGC)는 2025년 6월분에 대해 미국 증권거래위원회(SEC)에 Form 6-K를 제출했습니다. 이번 제출은 주로 행정적인 성격이며, Nasdaq 규칙 5250(c)(2)에 따라 감사되지 않은 간략 통합 중간 재무상태표 및 2024년 12월 31일 종료된 6개월 기간의 영업실적 및 포괄손실 보고서제공합니다. 해당 재무제표는 “Regencell Bioscience Holdings Limited, 2025년 상반기 경영 재무 결과 발표”라는 제목의 첨부서류 99.1로 제공됩니다. 제출 문서 본문에는 상세한 항목별 재무 데이터, 수익 전망 또는 전략적 계획이 포함되어 있지 않습니다. 또한, Regencell이 계속해서 연례 보고서를 Form 20-F로 제출하고 있음을 확인하는 표준 서명 및 제출 표지 정보도 포함되어 있습니다.

실제 재무 표는 첨부된 서류에만 포함되어 있고 제출 문서 본문에는 없기 때문에, 투자자들은 수익 동향, 수익성, 유동성 또는 기타 주요 성과 지표를 평가하기 위해 별도로 첨부서류 99.1을 검토해야 합니다. 전반적으로 이번 제출은 일상적인 것으로 보이며, 주요 거래, 자본 조달 또는 기업 지배구조 변경 사항을 발표하지 않습니다.

Regencell Bioscience Holdings Limited (RGC) a déposé un formulaire 6-K auprès de la SEC américaine pour le mois de juin 2025. Cette soumission est principalement de nature administrative et fournit, conformément à la règle Nasdaq 5250(c)(2), les bilans consolidés intermédiaires condensés non audités ainsi que les comptes de résultat et pertes globales pour la période de six mois close le 31 décembre 2024. Ces états financiers sont fournis en tant que Pièce 99.1, intitulée « Regencell Bioscience Holdings Limited annonce les résultats financiers de la première moitié de 2025 ». Aucun détail financier par poste, prévisions de bénéfices ou initiatives stratégiques ne figure dans le corps du document. Le document contient également les informations standard relatives aux signatures et à la couverture de dépôt confirmant que Regencell continue de déposer ses rapports annuels sur le formulaire 20-F.

Étant donné que les tableaux financiers réels sont présentés uniquement dans la pièce jointe et non dans le texte du dépôt, les investisseurs devront consulter séparément la Pièce 99.1 pour évaluer les tendances des revenus, la rentabilité, la liquidité ou d’autres indicateurs clés de performance. Dans l’ensemble, le dépôt semble routinier et n’annonce aucune transaction majeure, levée de fonds ou changement dans la gouvernance d’entreprise.

Regencell Bioscience Holdings Limited (RGC) reichte ein Formular 6-K bei der US-SEC für den Monat Juni 2025 ein. Die Einreichung ist hauptsächlich administrativer Natur und liefert gemäß Nasdaq-Regel 5250(c)(2) die ungeprüften, verkürzten konsolidierten Zwischenbilanzen sowie Gewinn- und Verlustrechnungen und Gesamtergebnisrechnungen für den sechsmonatigen Zeitraum zum 31. Dezember 2024. Diese Finanzberichte sind als Anlage 99.1 beigefügt und tragen den Titel „Regencell Bioscience Holdings Limited gibt Management-Finanzergebnisse für das erste Halbjahr 2025 bekannt.“ Im Haupttext der Einreichung sind keine detaillierten Finanzdaten nach Position, Gewinnprognosen oder strategischen Initiativen enthalten. Das Dokument enthält zudem die üblichen Unterschrifts- und Einreichungsinformationen, die bestätigen, dass Regencell weiterhin seine Jahresberichte in Form 20-F einreicht.

Da die eigentlichen Finanztabellen nur im Anhang und nicht im Text der Einreichung enthalten sind, müssen Anleger Anlage 99.1 separat prüfen, um Umsatztrends, Rentabilität, Liquidität oder andere wichtige Leistungskennzahlen zu bewerten. Insgesamt wirkt die Einreichung routinemäßig und kündigt keine wesentlichen Transaktionen, Kapitalerhöhungen oder Änderungen in der Unternehmensführung an.

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Commission File Number 001-41573

 

HIGH-TREND INTERNATIONAL GROUP
(Translation of registrant’s name into English)

 

60 Paya Lebar Road

#06-17 Paya Lebar Square

Singapore 409051

(65) 8304 8372

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F Form 40-F

 

 

 

 

 

 

EXPLANATORY NOTE

 

On June 27, 2025, High-Trend International Group (the “Company”) received a deficiency letter (the “Nasdaq Bid Price Deficiency Letter”) from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s ordinary shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq Bid Price Deficiency Letter has no immediate effect on the listing of the Company’s ordinary shares, and its ordinary shares will continue to trade on The Nasdaq Capital Market under the symbol “HTCO” at this time.

 

Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until December 24, 2025, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance with Rule 5550(a)(2) will be regained.

 

In the event the Company does not regain compliance in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company will also need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the NASDAQ staff that the Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by NASDAQ.

 

The Company intends to actively monitor the closing bid price for its ordinary shares and will consider available options to resolve the deficiency and regain compliance with Rule 5550(a)(2).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: June 30, 2025 HIGH-TREND INTERNATIONAL GROUP
   
  By: /s/ Shixuan He
    Shixuan He
    Chief Executive Officer
    (Principal Executive Officer)

 

 

2

 

 

FAQ

What did Regencell Bioscience (RGC) file on June 30, 2025?

RGC filed a Form 6-K furnishing its unaudited interim balance sheets and income statements for the six months ended December 31, 2024.

Does the 6-K include detailed financial results for Regencell?

No. The body of the filing references financials but detailed numbers are only in Exhibit 99.1, not reproduced in the main text.

Are there any major transactions or strategic updates disclosed?

The filing does not announce any acquisitions, capital raises, or strategic initiatives—only routine financial reporting.

Which form does Regencell use for its annual reports?

The company confirms it files annual reports under Form 20-F rather than Form 40-F.

Why is this 6-K considered routine?

It fulfills Nasdaq Rule 5250(c)(2) by providing interim statements; no material events or guidance changes are disclosed.
High-Trend International Group

NASDAQ:HTCO

HTCO Rankings

HTCO Latest News

HTCO Latest SEC Filings

HTCO Stock Data

23.18M
39.81M
68.97%
0.11%
0.05%
Marine Shipping
Industrials
Link
Hong Kong
Causeway Bay